finding is the "geographic atrophy" (GA), which is characterized by the loss of large areas of RPE and outer retina layers. 11 The prevalence of "wet" or "neovascular" AMD is about 15%-20% and it affects about 2% of the population above 60 years of age. Its course is often rapid and progressive and is characterized by the development of "choroidal neovascularization" (CNV), abnormal blood vessels generally originating from the choroid. 12, 13 CNV develops through BM defects as a result of the imbalance between the vascular endothelial growth factor (VEGF) that stimulates vascular growth and the pigment epithelialderived factor (PEDF) that suppresses vascular growth. 14 Three major patterns of CNV development have been described: type 1 or "sub-RPE" or "occult" CNV where abnormal vessels penetrate BM growing beneath the RPE; type 2 or "subretinal" or "classic" CNV in which neovessels grow in the subretinal space; otherwise, an anastomosis between retinal vessels and CNV can occur; this phenomenon is known as "retinal angiomatous proliferation" (RAP) or type 3 CNV. 6, [15] [16] [17] CNV might be associated with hemorrhages and serous exudates (subretinal, intraretinal, and sub-RPE) leading to photoreceptors loss, RPE damage, and severe vision impairment. 6 In this way, imaging devices with high sensitivity and specificity in identifying early signs of AMD and allowing accurate follow-up play a crucial role in the management of such a widespread disease.
Over the years, different technologies have been applied to image retinal and choroidal vascularizations and alterations occurring in the course of AMD. Fluorescein angiography (FA) has always been considered the gold standard for the diagnosis, classification, localization, and activity monitoring of CNVs. [18] [19] [20] Indocyanine green angiography (ICGA) is crucial for the diagnosis of neovascular AMD, due to its ability to image sub-RPE structures and to identify the presence and extension of the neovascular lesions. 21 Both FA and ICGA are invasive examinations since they require intravenous dye injection: nausea, vomiting, and serious anaphylactic reactions, although rarely, can occur. 22, 23 Over the past 20 years, optical coherence tomography (OCT) and, in particular, the spectral domain OCT (SD-OCT), has radically changed the diagnostic approach to macular diseases by offering a noninvasive imaging method, highly sensitive in identifying retinal and subretinal abnormalities associated with both neovascular or dry AMD. 24, 25 However, OCT has many limitations, especially in identifying neovascular tissue because of a similar reflectivity with drusenoid material, hemorrhage, and subretinal hyperreflective exudation.
In 2012, Jia et al. 26 introduced a new technique to enhance the OCT visualization of retinal and choroidal perfusion: this was called OCT angiography (OCT-A). OCT-A allows to visualize retinal and choroidal vasculature in three dimensions, without any dye injection and, therefore, in a totally noninvasive manner. [26] [27] [28] [29] [30] [31] [32] [33] [34] OCT-A principle is based on the possibility of distinguishing, in a steady eye, the movement related to blood cells flowing inside vessels from static tissues. The blood cells' motion can be displayed as a grayscale image by computing the decorrelation of signal amplitude between consecutive B-scans taken at the same retinal location: in this way a contrast between static and nonstatic tissue is generated. 26, 28, 29 OCT angiograms are derived from repeated structural B-scans, therefore they are perfectly co-registered with morphological data. Hence, OCT-A enables a simultaneous assessment of structural and functional retinal or choroidal features.
OCT-A imaging interpretation is generally performed on circular scan (C-scan) or "en face" images. To visualize blood flow at different retinal or choroidal layers, C-scans can be moved at different depths: from the inner retinal layers, where the superficial and deep capillary plexuses are located to the deep choroid. Outer retinal layers are normally avascular, therefore, no decorrelation signal could be appreciated at this level. External to the BM is the choriocapillaris (CC): this layer appears as a highly decorrelated, homogeneous, vascular texture. Single capillaries may not be distinguished because their maximum diameter is smaller than the lateral or transverse resolutions of the OCT-device. Deeper choroidal layers (Sattler's or Haller's layers) are actually difficult to be imaged because of the reflectivity of the structures above, the blood flow intensity of the CC, the decay of the light power, and the same wavelength of the light source.
The purpose of this review article is to report how to translate the theoretical usefulness of OCT angiography to the clinical management of exudative and nonexudative types of AMD.
OCT-A findings in AMD

Qualitative findings
Choroidal neovascular lesion subtypes. One of the first applications of OCT-A was in detecting the CNV presence and establishing its position in relation to RPE and BM, and thereby classifying the CNV as type 1, type 2, type 3, or mixed lesions (Table 1) . Jia et al. 35 in 2014 conducted a pioneering work using color OCT cross-sectional angiograms that combined flow and structural information. They reported how "en face" OCT angiograms, due to the longer wavelength used by OCT, showed a more distinct CNV vascular pattern than FA, since it is less obscured by overlying subretinal hemorrhages or exudation.
Sub-RPE, type 1 or occult CNV. Type 1 CNV is located under the RPE and it is typically associated with an RPE detachment. Because of its occult nature and location under the RPE, it has always been challenging to visualize the microvascular complex using conventional angiography or structural OCT. Kuehlewein et al. 31 showed that OCT-A provided the opportunity to directly visualize the occult CNV in AMD and its microvascular details. Through OCT-A, they identified two distinct type 1 CNV morphologies: the "medusa" and the "sea-fan" patterns. In the first one, vessels branched in all directions from the center of the lesion, where a large vessel trunk was identified, while in the second, more than 90% of the vessels radiated from only one side of the lesion. There were no statistically significant correlations between the two morphological patterns of the CNV and the RPE detachment subtype by spectral domain OCT analysis, nor with the number of intravitreal anti-VEGF injections received before imaging. Thus, "medusa" or "sea-fan" shapes may represent independent patterns not passing through a sequential stage. Coscas et al. 36 aimed to analyze whether there was a correspondence between different CNV patterns, identified on OCT-A, and treatment decisions that straightly depend on the active or quiescent status of the lesions. The CNV pattern based on OCT-A imaging alone was compared with the assessment made using traditional multimodal imaging, which was considered as the ground truth in defining the treatment decision. They demonstrated a high degree of concordance between different CNV patterns on OCT-A and treatment decisions based on traditional multimodal imaging. Sulzbacher et al. 37 tried to suggest a novel classification for wet AMD based on OCT-A findings and to correlate morphological features of CNV with the clinical criteria of disease activity. In treatment-naive CNV, CNV morphology showed a dense-net (DN) configuration in 12 of 14 eyes and a loose-net (LN) configuration or an unidentifiable CNV pattern in the remaining two eyes. In treated CNVs, DN was registered in 43.2%, LN in 27%, DN with additional LN (mixed type) in 14.9%, and an unidentifiable CNV pattern in 14.9%. Clinical correlations revealed significantly longer disease duration for LN with a median value of 4.3 years compared to 2.0 years of the DN.
Recently, Al-Sheikh et al. 38 tried to identify potential biomarkers of activity of both active and quiescent AMDrelated CNV, before and after treatment with anti-VEGF. They analyzed morphologic features and performed a quantitative measurement of the CNVs on OCT angiograms. In all, 100% of quiescent CNVs and 63.6% of the active CNVs demonstrated a prominent central vessel. Active lesions also showed a statistically significant greater rate of small vessel branching (82%) and peripheral arcades (82%) than quiescent lesions (30% and 40%, respectively). There were also no statistically significant differences in terms of lesion area and vessel density after treatment or compared to quiescent lesions. Fractal dimension analysis revealed that the lesion pattern complexity was significantly lower in the inner part of the lesion after treatment and in quiescent CNVs compared with active CNVs. Faridi et al. 39 evaluated the sensitivity and specificity of OCT-A in CNV detection compared to the gold --Medusa form-central large vessel trunk with radiating vessel in all directions --Sea-fan form-central large vessel trunk with radiating vessels in one direction --Indistinct-no obvious pattern or lack of details Sulzbacher et al. 37 --LN-well-defined vessel with low branching index --DN-fine vessels with dense capillary branching --Mixed type-50% lesion with low branching index and the rest 50% with dense capillary branching --Unidentifiable CNV pattern-new vessel not detected Miere --Medusa-shaped lesion-compact zone of new vessels with hypodensity inside --Glomerulus-shaped lesion-globular structure of intertwined vessels with interspersed hypodensity Coscas et al. 36 Active CNV if at least three features were present standard FA. The outcomes of a combined "en face" and cross-sectional OCT-A approached those of the gold standard of combined FA and OCT. Structural OCT alone demonstrated excellent sensitivity for CNV detection, but OCT-A could mitigate false positives by adding flow information.
OCT-A also allowed to describe type 1 CNV associated with particular pathological conditions. Naysan et al. 32 documented type 1 CNV in the setting of dome-shaped macula, that is, an inward bulge of the macula within a posterior staphyloma in highly myopic patients. Dansingani et al. 33 applied OCT-A to identify type 1 CNVs in pachychoroid spectrum diseases associated with shallow irregular pigment epithelium detachment (PED). OCT-A proved to be effective in detecting neovascular lesions when choroidal hyperpermeability and chronic alterations of RPE and outer retina could compromise the diagnostic sensitivity of dye-based angiography for type 1 CNVs.
McClintic et al. 40 investigated the feasibility of phasevariance OCT-A (PV-OCT-A) in detecting vascularized PEDs (vPEDs) in AMD. Neovascularization may occur in as many as 34% of PEDs and has been associated with worse visual outcomes and an increased risk of potentially catastrophic complications, as RPE tears and subretinal hemorrhage. PV-OCTA was reported to be safe and able to allow earlier and more frequent assessments.
Veronese et al. 41 showed the capability of OCT-A to differentiate between various types of PEDs. They assumed that there are not only vPEDs that are most commonly correlated with neovascular AMD but also drusenoid and serous PEDs as features of non-neovascular AMDs. Using SD OCT-A, they classified vPEDs into two different subtypes according to certain imaging features: acute, flat, irregular vPED and chronic dome-shaped vPED. They reported a correlation between vPED extension and CNV features. In acute, flat, irregular vPEDs, CNV structures appeared monolayered on OCT-A, whereas chronic domeshaped vPEDs were associated with multilayered CNV on OCT-A.
Palejwala et al. 42 showed how OCT-A could identify type 1 CNV associated with no sign of exudation. OCT-A detected the presence of abnormal pattern of vascular flow above the BM, and it was therefore possible to detect CNV that did not leak on FA. Therefore, while FA and structural OCT are primarily able to identify exudation from CNV rather than the CNV itself, OCT-A is not dependent on the presence of vascular leakage and is able to detect both nonexudative and exudative CNVs. They proposed that neovascular AMD could be classified into two phenotypes: exudative neovascular AMD (traditional entity) and nonexudative neovascular AMD (novel entity).
Type 2 (or Classic CNV) and mixed lesions. Type 2 neovascularization in AMD originates from the choroid and it is located above the RPE in the subretinal space. 43 Kuehlewein et al. 30 described a large type 2 neovascular pattern lesion on OCT angiograms. This CNV showed two large central trunks or feeder vessels, one superior and the other inferior, and a branching network of dense smaller caliber vessels radiating in all directions from the main trunk.
El Ameen et al. 44 reported different type 2 CNV patterns on OCT-A: the "medusa-shaped" complex and the "glomerulus-shaped" complex. The medusa-shaped lesion was described as a compact zone of small new blood vessels with a minimal hypodense structure inside. The glomerulus-shaped lesion was defined per comparison with the kidney glomerulus, as harboring globular structures of entwined vessels separated by hypodense spaces.
Types 1 and 2 may coexist in the same neovascularization: this lesion was once called "minimally classic" CNV. Coscas et al. 45 described on OCT angiograms the modification of a mixed type 1 and 2 CNV during intravitreal VEGF-trap treatment. OCT-A was also found to be effective in distinguishing vascular from avascular components in the subretinal hyperreflective material, a common finding in exudative AMD. 46 Type 3 CNVs or retinal angiomatous proliferation. OCT-A has been applied for evaluation of type 3 CNVs. 37, 47, 48 Dansingani et al. 47 first applied OCT-A in the early diagnosis of type 3 CNVs and in assessing their response to treatment. The detection of type 3 CNV may be difficult in the early stages, when it may exclusively show intraretinal hyperreflective features on structural OCT, without retinal thickening or RPE disruption. They reported that manual "en face" segmentation enhanced the sensitivity of OCT-A in detecting these lesions by excluding the flow signals from the inner retinal capillaries. This careful segmentation allowed to reveal a complex of dilated capillaries, with abnormal flow, in the deep capillary plexus suggesting the potential origin of type 3 CNVs. Miere et al. 49 have also shown a similar contribution of OCT-A in the early diagnosis of this type of CNV. Moreover, Kuehlewein et al. 50 showed the connection between the deep capillary plexus and the small intraretinal neovascular complexes using OCT-A.
Polypoidal choroidal vasculopathy. ICGA has always been the gold standard for the diagnosis and management of polypoidal choroidal vasculopathy (PCV). OCT-A could be considered a noninvasive alternative, having the potential to resolve vascular networks along the z-axis and therefore to provide greater information concerning spatial relationships between pathological vascular tissue and the surrounding retinal and choroidal layers. 51, 52 On structural brightness scans (B-scans), polypoidal lesions, branching vascular network (BVN), and type 1 CNV can be localized between RPE and BM. Inoue et al. 51 showed that the capability of visualizing BVNs through OCT-A was comparable to ICGA and that the signal within BVNs was relatively homogeneous. Conversely, they demonstrated that polyps were poorly visualized and that the signal within the polyps was clear in most of the cases but nonuniform. This may be justified by the description of polyps as aneurysmal dilations with a focal region of altered flow, as previously reported by Miura et al. 53 Srour et al. 54 described the morphological features of polyps on OCT-A either as a "hypoflow" round structure, or as a "hyperflow" round structure surrounded by a hypointense halo. They also reported that the BVN was always clearly detected on OCT angiograms.
Choriocapillaris perfusion changes in neovascular-AMD. Jia et al. 35 and Coscas et al. 36 described the presence of flowvoid regions adjacent to the CNV at the level of the CC. Both hypothesized that these areas corresponded to focal choroidal hypoperfusion and might have a role in the pathogenesis of CNVs. This hypothesis has been supported by histologic studies that have identified abnormalities in choroidal perfusion in AMD. 55 Molt et al. 28 observed that all CNV lesions, on OCT angiograms, were associated with areas of CC alteration, either corresponding to flow impairment and/or atrophy. Cicinelli et al. 56 reported the presence of significant choroidal vascular depletion and fibrotic replacement in patients with non-neovascular AMD, suggesting a potential implication in the pathogenesis and progression of the disease. A recent study demonstrated how intermediate AMD eyes of patients with neovascular AMD in the fellow eye have an increased average CC signal void size compared to eyes without neovascular AMD in the fellow eye. 57 Kuehlewein et al. 31 noted hypoperfusion of the CC surrounding the type 1 neovascular complex in four eyes. They hypothesized that type 1 CNV may develop as a result of a primitive alteration of the CC, since the ischemia resulting from CC loss may induce vasogenic cytokines release from the RPE, leading to neovascularization. 58 In all cases, the neovascular complex was surrounded by a dark area located in the CC layer, presenting a halo-like shape. This dark aspect on OCT-A could probably be due to a decrease in flow density, explaining the nonvisualization of the vasculature.
Geographic atrophy. The hallmark of advanced nonexudative AMD is the formation of GA, which is characterized by the loss of photoreceptors, RPE, and CC. 55, 59 OCT does not allow to visualize the pathologic vascular changes, while FA and ICGA have had limited utility in assessing nonexudative AMD with GA. Choi et al. 27 reported the utility of OCT-A in assessing the features and progression of GA. OCT-A was able to reveal CC alterations beyond the GA margin in 10 of the 12 analyzed eyes. Using a custombuilt software based on a variable interscan time analysis, they showed that CC flow impairment outside the GA regions was less pronounced than flow impairment within the GA regions. Moreover, previously undiagnosed and clinically silent CNVs were detected using OCT-A and these lesions existed over surviving RPE cells. According to similar findings, 60, 61 it was hypothesized that CNV is associated with surviving RPE because the RPE cells provide the stimulus for the formation or stabilization of new blood vessels. Similar findings were reported by Capuano et al. 62 and they also evaluated that around 25% of the quiescent CNVs in case of GA may develop some degree of exudation.
Quantitative findings
One of the most interesting applications of OCT-A is the possibility to define some quantitative aspects related to neovascular lesions and other abnormalities associated with AMD. The possibility to calculate the extent of a vascular lesion allows to understand its spatial evolution over time and its structural response to treatment. Until today, many mathematical formulas or algorithms have been applied to obtain these data.
Jia et al. 35 calculated the CNV area and flow index from neovascular AMD cases. To quantify the blood flow within the CNV, CNV area and flow index were computed from the two-dimensional (2D) maximum projection outer retina OCT angiogram. CNV area was calculated by multiplying the number of pixels (for which the decorrelation value was above that of the background) and the pixel size. Flow index was a dimensionless parameter between 0 and 1 that was proportional to the density of blood vessels and the velocity of blood flow in the CNV area. A high flow index indicated active blood flow within the CNV. Higher flow was detected with larger CNVs and those that were type 2 compared with type 1 and mixed CNVs.
Kuehlewein et al. 30, 31 performed a quantitative analysis of type 1 and type 2 CNVs using the publicly available GNU Image Manipulation Program GIMP 2.8.14 (http:// gimp.org) and the Free Select, Measure, and Threshold tools of the publicly available image processing software ImageJ (public domain software, National Institute of Health, Bethesda, MD, USA). For each examination, the lesion area was assessed in pixels and converted to square millimeters. Vessel density was assessed with OCT-A by converting the en face images into binary images using a threshold that was manually adjusted to best visualize the vessels of the CNV. Vessel density was then calculated as a percent area of the lesion occupied by the vessels. A reduction in size and vessel density of the CNVs was noted after treatment with anti-VEGF only for type 2 lesions. They hypothesized that type 1 CNVs were mature, long-standing neovascular complexes, and therefore resistant to therapy.
Muakkassa et al. 58 used ImageJ to measure the area, the perimeter, and the greatest linear dimension (GLD) of CNVs on en face OCT angiograms. They reported decreases in CNV GLD and area with an average reduction of 23.6% and 29.8%, respectively.
Coscas et al. 45 used an in-built OCT-A software (Heyex Software Version 1.9.201.0; Heidelberg Engineering) for analyzing mixed type 1 and 2 CNVs after intravitreal VEGF trap treatment. The area of CNV was computed by manually outlining the border of the neovascular lesion for both type 1 and type 2 components. A significant reduction in terms of area and GLD was demonstrated for both neovascular components, with a clear prevalence of that of type 2. Palejwala et al. 42 proposed a quantitative analysis method based on a custom software written in MATLAB (MathWorks, Natick, MA, USA). The CNV area was calculated on a binary image of the total area of vessels with active blood flow within the CNV network. They showed how the CNV flow area progressively enlarged along with the time without signs of exudation on OCT or vision loss.
Recently, Nesper et al. 63 proposed a new OCT-A postprocessing approach to facilitate the visualization and interpretation of lesions in AMD with coexisting GA and CNV. The typical anterior displacement of larger choroidal vessels in atrophy should be always considered in order to avoid misinterpreting these vessels as CNV on "en face" OCT-A. They observed that medium-sized choroidal vessels were displaced anteriorly in areas of atrophy in 100% of the examined eyes in the CC slab and in the outer retinal slab in 75% of eyes. Cross-sectional OCT-A was used to confirm the presence of CNV and for distinguishing it from choroidal vessels. This post-processing approach could facilitate the interpretation of en face OCT angiograms, improving the OCT-A sensitivity in the characterizing choroidal structures.
OCT angiography findings in treated AMD
In many studies we have already considered, the authors tried to understand the utility of OCT-A during the followup of patients with exudative AMD who underwent intravitreal treatment. Spaide 14 highlighted how the depth-resolved nature of OCT-A allowed to segment CNVs showing their true anatomy and the treatment-induced morphological changes. OCT-A showed how, conversely to what had been previously assumed, the hypothesis of vascular normalization in eyes receiving periodic antiangiogenic treatment could not be supported. In fact, he described an "abnormalization" of the vessels in treated eyes. Vessels in eyes having recurrent anti-VEGF treatment were larger and displayed numerous connections between the efferent and afferent vessels of the CNV. "Abnormalization" of the vessels may be explained by periodic pruning of angiogenic vascular sprouts by VEGF withdrawal induced by the drug. Kuehlewein et al. 30 reported that in eyes with type 2 neovascularization, after ranibizumab therapy the main central trunk or "feeder vessel" remained unchanged. This large vessel was considered part of a mature neovascular complex associated with chronic multilayered RPE detachment. The resistance to anti-VEGF therapy might be explained by the presence of pericytes overlying the endothelial cells, whereas the smaller vessels consist of unprotected endothelial cells and are therefore more sensitive to anti-VEGF therapy. 64, 65 Coscas et al. 45 observed a substantial decrease in terms of visibility of tiny branching vessels and anastomoses both in type 1 and 2 components of a mixed neovascular complex, associated with persistence of a clear hyperintense signal coming from larger trunks. The difference in response to VEGF-trap treatment between the two components of the lesion (24% area reduction for type 2 vs 11.3% area reduction for type 1) could probably be explained by the different location of the lesions. The type 2 component, due to the pre-epithelial localization, might have been more easily reached by the injected drug versus the type 1 component, which is, at least partially, masked by the RPE. Lumbroso et al. 66 studied, through OCT-A, the early morphologic evolution of treatment of naïve type 2 CNVs after repeated intravitreous anti-VEGF treatment. They concluded that OCT-A might be useful in understanding the needed time to visualize changes after each treatment session and in guiding the proper selection of the time interval between injections. Huang et al. 67 reported that a frequently performed OCT-A could show a dramatic shutdown of CNV flow in the initial 2 weeks after antiangiogenic injection, followed by the reappearance of channels at 4 weeks and re-accumulation of fluids at 6 weeks. They suggested that OCT-A performed every 2 weeks might be appropriate for determining the rate of CNV flow area change and could provide information on the extension of treatment interval.
Miere et al. 68 performed a qualitative assessment on OCT angiograms of treated type 3 CNVs and showed that the "tuft-shaped" abnormal outer retinal lesion after 1 year of anti-VEGF therapy either becomes undetectable or develops sub-RPE neovascularization.
OCT-A qualitative and quantitative assessments of CNVs may be an additional way to follow the response to therapy, providing additional information for treatment decisions that generally solely rely on the presence or absence of fluid on OCT B-scans. 58 
Limitations of OCT-A in AMD
Despite the multiple advantages of OCT-A, it is a relatively recent tool and shows several limitations. Actually, some limits that were identified in early studies on OCT-A have been resolved by the advent of the latest upgrades. Jia et al. 26 highlighted the need for higher scanning speed to provide a sufficient cross-sectional frame rate to overcome background eye motion and to provide a larger scanning. One of the most significant issues concerns the fact that vasculature can cast angiographic shadows onto the layers below. As Molt et al. 28 observed, CC alterations underneath CNVs were relatively difficult to visualize due to the shadow graphic artifact that a CNV lesion created on the CC en face OCT angiograms. Kuehlewein et al. 31 observed how projection artifact could sometimes make it difficult to distinguish normal physiological vessels from pathological ones. However, software providing an "artifacts removal" function is now available. This approach subtracts projection artifact from superficial vessels, but may also cause some loss of signal of pathological blood vessels.
Another major OCT-A limit concerns the segmentation. "En face" imaging relies on segmentation strategies and may lead to corrupted images when these strategies are wrong. A diseased retinal infiltration (i.e. exudative AMD), determining potential misalignments between automated segmentation and retinal layer's borders, is likely to cause segmentation strategies to fail. When the segmentation algorithms fail from any cause, the layers of vessels are visualized together, or partially, in ways that do not reflect the true anatomy. Several studies pointed out the importance of a manual definition of the inner and outer boundaries of the C-scan section including all the areas suspicious for CNV. 16, 28, 36 Other limitations of OCT-A may be due to bulk motions: mydriasis and full patient cooperation seemed to be crucial for the final imaging quality. 30 
Conclusion
OCT-A offers several advantages over conventional dyebased techniques in imaging AMD. OCT-A is noninvasive and extremely fast, so it can be performed during each step of the entire follow-up of AMD patients. The depth-resolved nature of OCT-A and being intrinsically co-registered with structural OCT provide all the needed data for the diagnostic process and the treatment decisions. Despite the actual limitations, OCT-A is already becoming an indispensable tool in the daily clinical practice for managing patients with AMD.
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